NFE2L2 and coronary artery disorder: While no clinical trials have tested the use of NRF2 activating drugs in CAD patients, Turley et al. [47] did evaluate the effect of tert-butylhydroquinone (tBHQ), a commonly used food additive and known NRF2 activating substance, on NRF2 expression in vitro in the THP-1 monocyte cell line.